Research programme: anticancer therapeutics - Medpacto

Drug Profile

Research programme: anticancer therapeutics - Medpacto

Alternative Names: TEW 0201; UAI 201

Latest Information Update: 13 Jun 2014

Price : $50

At a glance

  • Originator YOUAI
  • Developer MedPacto
  • Class Small molecules; Sulfonamides
  • Mechanism of Action Proto oncogene protein b raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Colorectal cancer; Malignant melanoma

Most Recent Events

  • 01 Jul 2013 Preclinical trials in Cancer in South Korea (unspecified route)
  • 01 Jul 2013 Preclinical trials in Colorectal cancer in South Korea (unspecified route)
  • 01 Jul 2013 Preclinical trials in Malignant melanoma in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top